Effects of Alprazolam on Cholecystokinin-Tetrapeptide-Induced Panic and Hypothalamic–Pituitary–Adrenal-Axis Activity: A Placebo-Controlled Study

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Neuropsychopharmacology

• Publication date

  2003-03-26

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1038/sj.npp.1300131PMID 12700707
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neuropsychopharmacology

  2003cited by this paper
• Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings.

  2001cited by this paper
• Persistent respiratory irregularity in patients with panic disorder.

  2001cited by this paper
• Vigabatrin Decreases Cholecystokinin-Tetrapeptide (CCK-4) Induced Panic in Healthy Volunteers

  2001cited by this paper
• Increased ACTH Concentrations Associated with Cholecystokinin Tetrapeptide-Induced Panic Attacks in Patients with Panic Disorder

  2000cited by this paper
• Behavioral, cardiovascular, and neuroendocrine profiles following CCK‐4 challenge in healthy volunteers: A comparison of panickers and nonpanickers

  1998cited by this paper
• The role of the β-noradrenergic system in cholecystokinin-tetrapeptide-induced panic symptoms

  1998cited by this paper
• Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks

  1997cited by this paper
• Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder.

  1997cited by this paper
• Cholecystokinin in anxiety.

  1996cited by this paper
• Placebo response in the treatment of panic disorder.

  1996cited by this paper
• Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers

  1994cited by this paper
• [Neuroendocrine effects of benzodiazepines].

  1994cited by this paper
• Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients.

  1994cited by this paper
• Benzodiazepines increase preprocholecystokinin messenger RNA levels in rat brain.

  1993cited by this paper
• CCK in animal and human research on anxiety.

  1993cited by this paper
• Effects of alprazolam on pituitary-adrenal and catecholaminergic responses to metabolic stress in humans.

  1992cited by this paper
• Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings.

  1992cited by this paper
• Adrenocorticotropin hormone response to diazepam in healthy young men.

  1992cited by this paper
• Neuroendocrine effects of diazepam in panic and generalized anxiety disorders.

  1991cited by this paper
• Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings.

  1991cited by this paper
• Neuroendocrine effects of benzodiazepines.

  1990cited by this paper
• Cholecystokinin-Tetrapeptide Induces Panic Attacks in Patients with Panic Disorder *

  1990cited by this paper
• Long-term diazepam treatment produces changes in cholecystokinin receptor binding in rat brain.

  1990cited by this paper
• Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings.

  1989cited by this paper
• Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings.

  1989cited by this paper
• Long-term benzodiazepine treatment reduces neuronal responsiveness to cholecystokinin: an electrophysiological study in the rat.

  1988cited by this paper
• Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment.

  1988cited by this paper
• Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III. Discontinuation effects.

  1988cited by this paper
• Measurement of lactate-induced panic and anxiety.

  1987cited by this paper
• Release of cholecystokinin from rat cerebral cortex in vivo: role of GABA and glutamate receptor systems.

  1987cited by this paper
• Afternoon cortisol levels before (spontaneous) and after suppression with dexamethasone or oxazepam in depressed patients.

  1986cited by this paper
• Different populations of GABAergic neurons in the visual cortex and hippocampus of cat contain somatostatin- or cholecystokinin- immunoreactive material

  1984cited by this paper
• Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurones

  1984cited by this paper

• Exploring the Toxicity and Therapeutic Potential of A. dahurica and A. pubescens in Zebrafish Larvae: Insights into Anxiety Treatment Mechanisms

  2025cites this paper
• TRPC4/5 inhibitors: Phase I results and proof of concept studies

  2024cites this paper
• Exploring clinical applications and long-term effectiveness of benzodiazepines: An integrated perspective on mechanisms, imaging, and personalized medicine.

  2024cites this paper
• Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy Males

  2023cites this paper
• Peripheral Biomarkers in DSM-5 Anxiety Disorders: An Updated Overview

  2020cites this paper
• GABAergic System in Stress: Implications of GABAergic Neuron Subpopulations and the Gut-Vagus-Brain Pathway

  2020cites this paper
• Copeptin in CCK-4-induced panic in healthy man: Sexual dimorphisms in secretion pattern and panic response, but no correlation of copeptin with panic symptoms.

  2019cites this paper
• Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition

  2017cites this paper
• Нейроэндокринные аспекты патогенеза и психофармакотерапии панического расстройства

  2016cites this paper
• Plasma Levels of Neuroactive Steroids in Panic Disorder Patients and Healthy Volunteers Following Pentagastrin versus Placebo Injections

  2016cites this paper
• Genetics in the Pathogenesis and Treatment of Panic and Anxiety

  2014cites this paper
• Evaluation of the effects of venlafaxine and pregabalin on the carbon dioxide inhalation models of Generalised Anxiety Disorder and panic

  2013cites this paper
• The effect of 6-week treatment with escitalopram on CCK-4 challenge: a placebo-controlled study in CCK-4-sensitive healthy volunteers.

  2013cites this paper
• Benzodiazepines counteract rostral anterior cingulate cortex activation induced by cholecystokinin-tetrapeptide in humans.

  2013cites this paper
• Temporal association of elevated cholecystokininergic tone and adolescent trauma is critical for posttraumatic stress disorder-like behavior in adult mice

  2013cites this paper
• Acute Shift in Glutamate Concentrations Following Experimentally Induced Panic with Cholecystokinin Tetrapeptide—A 3T-MRS Study in Healthy Subjects

  2013cites this paper
• INTERNATIONAL JOURNAL OF PHARMACY & LIFE SCIENCES Neuroactive steroids and neuropharmacological disorder

  2013cites this paper
• Neuroactive steroids and neuropharmacological disorder

  2013cites this paper
• Cholecystokinin system genes: associations with panic and other psychiatric disorders.

  2012cites this paper
• Effects of yoga on the autonomic nervous system, gamma-aminobutyric-acid, and allostasis in epilepsy, depression, and post-traumatic stress disorder.

  2012cites this paper
• Untitled Page

  2012cites this paper
• Glyoxalase-I mRNA expression and CCK-4 induced panic attacks.

  2011cites this paper
• One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: Investigation of neural correlates with BOLD MRI

  2011influential citation
• Experimental panic provocation in healthy man—a translational role in anti-panic drug development?

  2011cites this paper
• Biomarkers in development of psychotropic drugs

  2011cites this paper
• Increased plasma corticosterone levels after periaqueductal gray stimulation-induced escape reaction or panic attacks in rats.

  2011cites this paper
• Long-term anxiolytic and antidepressant-like behavioural effects of tiagabine, a selective GABA transporter-1 (GAT-1) inhibitor, coincide with a decrease in HPA system activity in C57BL/6 mice

  2010cites this paper
• Biomarkers and Surrogate Markers in Drug Development

  2010cites this paper
• The selective serotonin re-uptake inhibitor escitalopram modulates the panic response to cholecystokinin tetrapeptide in healthy men depending on 5-HTTLPR genotype.

  2009cites this paper
• The acute antipanic and anxiolytic activity of aerobic exercise in patients with panic disorder and healthy control subjects.

  2009cites this paper
• Neurobiology of repeated transcranial magnetic stimulation in the treatment of anxiety: a critical review

  2009cites this paper
• When the bispectral index (bis) can give false results.

  2009cites this paper
• Translocator Protein (18 kD) as Target for Anxiolytics Without Benzodiazepine-Like Side Effects

  2009cites this paper
• A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO2 models of experimental human anxiety

  2009cites this paper
• Impact of loudness dependency of auditory evoked potentials on the panic response to CCK-4.

  2009cites this paper
• Effects of the GABA-reuptake Inhibitor Tiagabine on Panic and Anxiety in Patients with Panic Disorder

  2009cites this paper
• Functional neuroanatomy of CCK‐4‐induced panic attacks in healthy volunteers

  2009cites this paper
• Neuroendocrine pathways in benzodiazepine dependence: new targets for research and therapy

  2008cites this paper
• The complex roles of neurosteroids in depression and anxiety disorders.

  2008cites this paper
• Contemporary dental photography: selection and application.

  2008cites this paper
• Impact of state and trait anxiety on the panic response to CCK-4

  2008cites this paper
• GABAergic and endocannabinoid dysfunction in anxiety - future therapeutic targets?

  2008cites this paper
• Independent component analysis applied to pharmacological magnetic resonance imaging (phMRI): new insights into the functional networks underlying panic attacks as induced by CCK-4.

  2008cites this paper
• Nocturnal urinary cortisol excretion over a randomized controlled trial with paroxetine vs. placebo combined with relaxation training or aerobic exercise in panic disorder.

  2008cites this paper
• Regional cerebral metabolic rate (positron emission tomography) during inhalation of nitrous oxide 50% in humans.

  2008cites this paper
• UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL FACULDADE DE MEDICINA PROGRAMA DE PÓS-GRADUAÇÃO EM MEDICINA: CIÊNCIAS MÉDICAS USO DE HIDRATO DE CLORAL PARA SEDAÇÃO EM UNIDADE DE TRATAMENTO INTENSIVO PEDIÁTRICA: INDICAÇÕES, EFEITOS ADVERSOS E FATORES DE RISCO ASSOCIADOS

  2008cites this paper
• Chapter 4.1 Peptide receptor ligands to treat anxiety disorders

  2008cites this paper
• Chapter 5.3 Experimental models: Panic and fear

  2008cites this paper
• Blockade humaner Mineralocorticoidrezeptoren: Einfluss auf experimentell ausgelöste Panikattacken und Stresshormonsekretion

  2008cites this paper
• Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study

  2007cites this paper
• Significant Increase in the Aggressive Behavior of Transgenic Mice Overexpressing Peripheral Progastrin Peptides: Associated Changes in CCK2 and Serotonin Receptors in the CNS

  2007cites this paper
• The use of nitrous oxide in paediatric anaesthetic practice in the United Kingdom: a questionnaire survey *

  2007cites this paper
• Der Einfluss der repetitiven Transkraniellen Magnetstimulation auf CCK-4-induzierte Panikattacken

  2007cites this paper
• Pharmacological models in healthy volunteers: their use in the clinical development of psychotropic drugs

  2007cites this paper
• Effects of repetitive transcranial magnetic stimulation (rTMS) on panic attacks induced by cholecystokinin-tetrapeptide (CCK-4).

  2007cites this paper
• Use of nitrous oxide and oxygen for conscious sedation to manage pain and anxiety.

  2007cites this paper
• Functional neuroanatomy of CCK-4-induced panic attacks in healthy volunteers.

  2007influential citation
• Update on bispectral index monitoring.

  2006cites this paper
• Reproductive outcomes among dental personnel: a review of selected exposures.

  2006cites this paper
• Neuroendokrinologische und psychophysiologische Auswirkungen von Musik als Mittel zur Stressreduzierung vor gynäkologischen Operationen

  2006cites this paper
• Behavioural and neurogenetic study of molecular mechanisms involved in regulation of exploratory behaviour in rodents

  2006cites this paper
• Modification of Behavior With 50% Nitrous Oxide/Oxygen Conscious Sedation Over Repeated Visits for Dental Treatment A 3-Year Prospective Study

  2006cites this paper
• A comparison of oral midazolam and nitrous oxide sedation for dental extractions in children

  2006cites this paper
• Attenuation of the hypothalamic-pituitary-adrenal axis responsivity to the Trier Social Stress Test by the benzodiazepine alprazolam.

  2006cites this paper
• Panic induction with cholecystokinin-tetrapeptide (CCK-4) Increases plasma concentrations of the neuroactive steroid 3alpha, 5alpha tetrahydrodeoxycorticosterone (3alpha, 5alpha-THDOC) in healthy volunteers.

  2005cites this paper
• Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder.

  2005cites this paper
• Randomized, Double-Blind Study of SR142801 (Osanetant). A Novel Neurokinin-3 (NK3) Receptor Antagonist in Panic Disorder with Pre- and Posttreatment Cholecystokinin Tetrapeptide (CCK-4) Challenges

  2005cites this paper
• Biomarkers in psychotropic drug development: integration of data across multiple domains.

  2005cites this paper
• Effects of a metabotropic glutamate2/3 receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results

  2005cites this paper
• Anxiolytic-like action in mice treated with nitrous oxide and oral triazolam or diazepam.

  2005cites this paper
• Does the panic attack activate the hypothalamic-pituitary-adrenal axis?

  2005cites this paper
• Preemptive analgesia at the crossroad.

  2005cites this paper
• Translational research in central nervous system drug discovery

  2005cites this paper
• Panic Induction with Cholecystokinin-Tetrapeptide (CCK-4) Increases Plasma Concentrations of the Neuroactive Steroid 3α, 5α Tetrahydrodeoxycorticosterone (3α, 5α-THDOC) in Healthy Volunteers

  2005cites this paper
• Challenge studies in anxiety disorders.

  2005cites this paper
• Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges.

  2005cites this paper
• Cardiovascular effects of xenon and nitrous oxide in patients during fentanyl‐midazolam anaesthesia *

  2004cites this paper
• Perceptions of dentists, dentistry undergraduate students, and the lay public about dental sedation.

  2004cites this paper
• The acute effects of L‐theanine in comparison with alprazolam on anticipatory anxiety in humans

  2004cites this paper
• A partially blinded randomised controlled trial of patient‐maintained propofol sedation and operator controlled midazolam sedation in third molar extractions

  2004cites this paper
• The effect of successful treatment on the emotional and physiological response to carbon dioxide inhalation in patients with panic disorder.

  2004cites this paper
• Nitrous Oxide Attenuates Pressor but Augments Norepinephrine Response to Laryngoscopy and Endotracheal Intubation

  2003cites this paper
• Randomized, controlled, cross-over clinical trial comparing intravenous midazolam sedation with nitrous oxide sedation in children undergoing dental extractions.

  2003cites this paper
• Relative analgesia and general dental practitioners: attitudes and intentions to provide conscious sedation for paediatric dental extractions.

  2003cites this paper
• Current awareness in human psychopharmacology

  2003cites this paper
• Current awareness in human psychopharmacology.

  2003cites this paper
• Nitrous oxide analgesia for minor pediatric surgical procedures: an effective alternative to conscious sedation?

  2003cites this paper
• [Evaluation of electroencephalographic parameters during the administration of different nitrous oxide concentrations.].

  2003cites this paper
• A randomised, controlled, crossover trial of oral midazolam and nitrous oxide for paediatric dental sedation

  2002cites this paper
• Nitrous oxide-oxygen or oral midazolam for pediatric outpatient sedation.

  2002cites this paper